Skip to main content
SpringerLink
Log in

Mirvetuximab soravtansine in folate receptor alpha-positive, platinum-resistant ovarian cancers: a profile of its use

  • Adis Drug Q&A
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

Abstract

Mirvetuximab soravtansine (ElahereTM), an antibody-drug conjugate carrying a maytansinoid payload targeting folate receptor alpha (FRα), is a valuable new treatment option for patients with FRα-positive, platinum-resistant ovarian cancer. Mirvetuximab soravtansine significantly improved objective response rates compared with historical rates in patients with FRα-positive, platinum-resistant ovarian cancer in the phase 2 SORAYA trial. In the confirmatory phase 3 MIRASOL trial, mirvetuximab soravtansine significantly improved median progression-free survival, objective response rates, and median overall survival compared with investigator’s choice of nonplatinum chemotherapy in patients with this indication. Mirvetuximab soravtansine has manageable tolerability, with eye disorders being the most common treatment-related adverse event.

Plain Language Summary

Platinum-resistant ovarian cancer has a poor prognosis, with limited effective and tolerable treatment options. Mirvetuximab soravtansine (ElahereTM) is an antibody-drug conjugate that delivers DM4 (the active anticancer component of mirvetuximab soravtansine) to ovarian cancer cells that overexpress the folate receptor alpha (FRα) protein, which is widely and almost exclusively found on epithelial cancers. In clinical trials, mirvetuximab soravtansine improves objective response rates, and prolongs progression-free and overall survival compared with the nonplatinum chemotherapies typically used to treat these patients. Mirvetuximab soravtansine has manageable tolerability, with eye disorders being the most common treatment-related adverse event. Mirvetuximab soravtansine is a valuable new treatment option for platinum-resistant ovarian cancers that overexpress FRα.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7–34.

    Article  PubMed  Google Scholar 

  2. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology: ovarian cancer including fallopian tube cancer and primary peritoneal cancer. 2023. https://www.nccn.org. Accessed 31 Jan 2024.

  3. Garzon S, Lagana AS, Casarin J, et al. Secondary and tertiary ovarian cancer recurrence: what is the best management? Gland Surg. 2020;9(4):1118–29.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Randall LM, Monk BJ. Bevacizumab toxicities and their management in ovarian cancer. Gynecol Oncol. 2010;117(3):497–504.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Gaillard S, Oaknin A, Ray-Coquard I, et al. Lurbinectedin versus pegylated liposomal doxorubicin or topotecan in patients with platinum-resistant ovarian cancer: a multicenter, randomized, controlled, open-label phase 3 study (CORAIL). Gynecol Oncol. 2021;163(2):237–45.

    Article  CAS  PubMed  Google Scholar 

  6. Hamanishi J, Takeshima N, Katsumata N, et al. Nivolumab versus gemcitabine or pegylated liposomal doxorubicin for patients with platinum-resistant ovarian cancer: open-label, randomized trial in Japan (NINJA). J Clin Oncol. 2021;39(33):3671–81.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Moore KN, Oza AM, Colombo N, et al. Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I. Ann Oncol. 2021;32(6):757–65.

    Article  CAS  PubMed  Google Scholar 

  8. Pujade-Lauraine E, Fujiwara K, Ledermann JA, et al. Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study. Lancet Oncol. 2021;22(7):1034–46.

    Article  CAS  PubMed  Google Scholar 

  9. Chelariu-Raicu A, Mahner S, Moore KN, et al. Integrating antibody drug conjugates in the management of gynecologic cancers. Int J Gynecol Cancer. 2023;33(3):420–9.

    Article  PubMed  Google Scholar 

  10. ImmunoGen I. ELAHERE™ (mirvetuximab soravtansine-gynx) injection, for intravenous use: US prescribing information. 2023. https://www.fda.gov. Accessed 31 Jan 2024.

  11. Roche. VENTANA FOLR1 (FOLR1-2.1) RxDx assay label. 2022. https://www.fda.gov. Accessed 31 Jan 2024.

  12. Ab O, Whiteman KR, Bartle LM, et al. IMGN853, a folate receptor-α (FRα)-targeting antibody-drug conjugate, exhibits potent targeted antitumor activity against FRα-expressing tumors. Mol Cancer Ther. 2015;14(7):1605–13.

    Article  CAS  PubMed  Google Scholar 

  13. Tolcher A, Hamilton E, Coleman RL. The evolving landscape of antibody-drug conjugates in gynecologic cancers. Cancer Treat Rev. 2023;116: 102546.

    Article  CAS  PubMed  Google Scholar 

  14. Moore KN, Borghaei H, O’Malley DM, et al. Phase 1 dose-escalation study of mirvetuximab soravtansine (IMGN853), a folate receptor α-targeting antibody-drug conjugate, in patients with solid tumors. Cancer. 2017;123(16):3080–7.

    Article  CAS  PubMed  Google Scholar 

  15. Moore KN, Martin LP, O’Malley DM, et al. Safety and activity of mirvetuximab soravtansine (IMGN853), a folate receptor alpha-targeting antibody-drug conjugate, in platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer: a phase I expansion study. J Clin Oncol. 2017;35(10):1112–8.

    Article  CAS  PubMed  Google Scholar 

  16. Moore KN, Angelergues A, Konecny GE, et al. Mirvetuximab soravtansine in FRα-positive, platinum-resistant ovarian cancer. N Engl J Med. 2023;389(23):2162–74.

    Article  CAS  PubMed  Google Scholar 

  17. Matulonis UA, Lorusso D, Oaknin A, et al. Efficacy and safety of mirvetuximab soravtansine in patients with platinum-resistant ovarian cancer with high folate receptor alpha expression: results from the SORAYA study. J Clin Oncol. 2023;41(13):2436–45.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Oaknin A, Lorusso D, Oza A, et al. Characterization of extended treatment benefit from three phase 1 and 3 clinical trials examining patients with folate receptor alpha-positive recurrent ovarian cancer treated with single-agent mirvetuximab soravtansine [abstract no. 2022-RA-660-ESGO and poster PA-048]. Int J Gynecol Cancer. 2022;32(Suppl 2):A251–2.

    Google Scholar 

  19. Moore K, Angelergues A, Konecny G, et al. Phase III MIRASOL (GOG 3045/ENGOT-ov55) study: initial report of mirvetuximab soravtansine vs. investigator’s choice of chemotherapy in platinum-resistant, advanced high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with high folate receptor-alpha expression [abstract no. LBA5507 plus poster]. J Clin Oncol. 2023;41(Suppl 17): LBA5507.

    Article  Google Scholar 

  20. Martin LP, Konner JA, Moore KN, et al. Characterization of folate receptor alpha (FRα) expression in archival tumor and biopsy samples from relapsed epithelial ovarian cancer patients: a phase I expansion study of the FRα-targeting antibody-drug conjugate mirvetuximab soravtansine. Gynecol Oncol. 2017;147(2):402–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Center for Drug Evaluation and Research. Multidisciplinary review (ElahereTM—761310Orig1s000). 2022. https://www.fda.gov. Accessed 31 Jan 2024.

  22. Moore KN, Lorusso D, Oaknin A, et al. Integrated safety summary of single-agent mirvetuximab soravtansine in patients with folate receptor (Fra)-positive recurrent ovarian cancer: phase 1 and 3 clinical trials [abstract no 5574 and poster]. J Clin Oncol. 2022;40(Suppl 16):2436–45.

    Google Scholar 

  23. US National Institutes of Health. A study of mirvetuximab soravtansine vs. investigator’s choice of chemotherapy in platinum-resistant, advanced high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with high folate receptor-alpha expression (MIRASOL). 2019. https://clinicaltrials.gov. Accessed 31 Jan 2024.

  24. US National Institutes of Health. A study of mirvetuximab soravtansine in platinum-resistant, advanced high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with high folate receptor-alpha expression (SORAYA). 2020. https://clinicaltrials.gov. Accessed 31 Jan 2024.

  25. Hendershot A, Slabaugh M, Riaz KM, et al. Strategies for prevention and management of ocular events occurring with mirvetuximab soravtansine. Gynecol Oncol Rep. 2023;47: 101155.

    Article  PubMed  PubMed Central  Google Scholar 

  26. Staff NP, Grisold A, Grisold W, et al. Chemotherapy-induced peripheral neuropathy: a current review. Ann Neurol. 2017;81(6):772–81.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

The manuscript was reviewed by: A. Davis, Medical Oncology, Canberra Hospital, Canberra, Australian Capital Territory, Australia; D. Roque, Department of Obstetrics and Gynecology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA. During the peer review process, ImmunoGen Inc., the marketing authorization holder of mirvetuximab soravtansine, was also offered an opportunity to provide a scientific accuracy review of their data. Changes resulting from comments received were made on the basis of scientific and editorial merit.

Author information

Authors and Affiliations

  1. Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand

    Simon Fung & Yahiya Y. Syed

Authors
  1. Simon Fung
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yahiya Y. Syed
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Simon Fung.

Ethics declarations

Funding

The preparation of this review was not supported by any external funding.

Authorship and conflict of interest

S. Fung and Y. Y. Syed are salaried employees of Adis International Ltd/Springer Nature and declare no relevant conflicts of interest. All authors contributed to this article and are responsible for its content.

Ethical approval, consent to participate, consent for publication, availability of data and material, code availability

Not applicable.

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary file1 (PDF 252 KB)

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Fung, S., Syed, Y.Y. Mirvetuximab soravtansine in folate receptor alpha-positive, platinum-resistant ovarian cancers: a profile of its use. Drugs Ther Perspect 40, 53–60 (2024). https://doi.org/10.1007/s40267-024-01050-3

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40267-024-01050-3

Search

Navigation